Douglas Armellino

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

Bruce I. Terman, Maureen Dougher-Vermazen, Miguel E. Carrion et al. · Biochemical and Biophysical Research Communications · 1992 · 1.5K citations

Life Sciences, Biochemistry, Molecular Biology +14

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 356 citations · Full text

Medicine, Medicinal Chemistry, Oncology +11

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

John F. DiJoseph, Maureen Dougher, Lyka B. Kalyandrug et al. · Clinical Cancer Research · 2006 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

John F. DiJoseph, Maureen Dougher, Douglas Armellino et al. · Leukemia · 2007 · 134 citations

Medicine, Oncology, Pharmacology +15

Distribution of angiotensin II receptors in rat and human adipocytes.

David L. Crandall, H. Herzlinger, Brian Saunders et al. · Journal of Lipid Research · 1994 · 100 citations · Full text

Medicine, Endocrinology, Pharmacology +10